Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B

Abstract

Aims: Assessing the diagnostic performances of APRI and FIB-4 using age as a categorical marker. Methods: 822 chronic hepatitis B (CHB) patients were included. Using METAVIR scoring system as a reference, the performances of APRI and FIB-4 were compared between patients aged≥30 and patients aged < 30 years. Results: The APRI AUROC in patients aged < 30 years was lower than that in patients aged≥30 years for significant fibrosis (0.61 vs 0.70, p < 0.001) and cirrhosis (0.64 vs 0.78, p < 0.001). The FIB-4 AUROC in patients aged < 30 years was lower than that in patients aged≥30 years for significant fibrosis (0.57 vs 0.65, p < 0.001) and cirrhosis (0.63 vs 0.72, p < 0.001). Using specificity≥90%, the APRI cut-off in patients aged < 30 years was lower than patients aged≥30 years for significant fibrosis (1.0 vs 1.2) and cirrhosis (1.2 vs 1.5). Using sensitivity≥90%, the APRI cut-off in patients aged < 30 years was also lower than patients aged≥30 years for significant fibrosis (0.2 vs 0.4) and cirrhosis (0.3 vs 0.5). Using specificity≥90%, the FIB-4 cut-off in patients aged < 30 years was lower than that in patients aged≥30 years for significant fibrosis (1.2 vs 2.1) and cirrhosis (1.4 vs 2.6). Using sensitivity≥90%, the FIB-4 cut-off in patients aged < 30 years was also lower than that in patients aged≥30 years for significant fibrosis (0.5 vs 0.8) and cirrhosis (0.8 vs 1.2). Conclusions: Evaluation of the diagnostic performances of APRI and FIB-4 should take age into consideration.